MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis

NASDAQ:MDXG • US6024961012

5.12 USD
+0.03 (+0.59%)
At close: Feb 13, 2026
5.12 USD
0 (0%)
After Hours: 2/13/2026, 8:23:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Overall MDXG gets a fundamental rating of 5 out of 10. We evaluated MDXG against 523 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. MDXG has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year MDXG was profitable.
  • In the past year MDXG had a positive cash flow from operations.
  • In multiple years MDXG reported negative net income over the last 5 years.
  • In multiple years MDXG reported negative operating cash flow during the last 5 years.
MDXG Yearly Net Income VS EBIT VS OCF VS FCFMDXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • MDXG has a Return On Assets of 12.80%. This is amongst the best in the industry. MDXG outperforms 94.46% of its industry peers.
  • MDXG's Return On Equity of 17.09% is amongst the best of the industry. MDXG outperforms 94.84% of its industry peers.
  • MDXG's Return On Invested Capital of 15.15% is amongst the best of the industry. MDXG outperforms 95.79% of its industry peers.
Industry RankSector Rank
ROA 12.8%
ROE 17.09%
ROIC 15.15%
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
MDXG Yearly ROA, ROE, ROICMDXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

  • Looking at the Profit Margin, with a value of 10.38%, MDXG belongs to the top of the industry, outperforming 91.20% of the companies in the same industry.
  • MDXG has a better Operating Margin (13.73%) than 92.73% of its industry peers.
  • MDXG's Operating Margin has been stable in the last couple of years.
  • MDXG has a Gross Margin of 81.99%. This is amongst the best in the industry. MDXG outperforms 85.66% of its industry peers.
  • MDXG's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.73%
PM (TTM) 10.38%
GM 81.99%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
MDXG Yearly Profit, Operating, Gross MarginsMDXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDXG is creating some value.
  • The number of shares outstanding for MDXG has been increased compared to 1 year ago.
  • The number of shares outstanding for MDXG has been increased compared to 5 years ago.
  • MDXG has a better debt/assets ratio than last year.
MDXG Yearly Shares OutstandingMDXG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
MDXG Yearly Total Debt VS Total AssetsMDXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • MDXG has an Altman-Z score of 7.93. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 7.93, MDXG is doing good in the industry, outperforming 79.16% of the companies in the same industry.
  • The Debt to FCF ratio of MDXG is 0.27, which is an excellent value as it means it would take MDXG, only 0.27 years of fcf income to pay off all of its debts.
  • MDXG's Debt to FCF ratio of 0.27 is amongst the best of the industry. MDXG outperforms 95.22% of its industry peers.
  • MDXG has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
  • MDXG has a Debt to Equity ratio of 0.07. This is in the lower half of the industry: MDXG underperforms 60.80% of its industry peers.
  • Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.27
Altman-Z 7.93
ROIC/WACC1.24
WACC12.23%
MDXG Yearly LT Debt VS Equity VS FCFMDXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
  • MDXG has a Current ratio of 4.41. This is comparable to the rest of the industry: MDXG outperforms 50.86% of its industry peers.
  • MDXG has a Quick Ratio of 3.95. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of MDXG (3.95) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.41
Quick Ratio 3.95
MDXG Yearly Current Assets VS Current LiabilitesMDXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for MDXG have decreased strongly by -35.71% in the last year.
  • Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 14.77% in the last year.
  • MDXG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.11% yearly.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%

3.2 Future

  • Based on estimates for the next years, MDXG will show a decrease in Earnings Per Share. The EPS will decrease by -5.49% on average per year.
  • MDXG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.49% yearly.
EPS Next Y16.07%
EPS Next 2Y-37.8%
EPS Next 3Y-5.49%
EPS Next 5YN/A
Revenue Next Year18%
Revenue Next 2Y7.11%
Revenue Next 3Y9.76%
Revenue Next 5Y14.49%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MDXG Yearly Revenue VS EstimatesMDXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
MDXG Yearly EPS VS EstimatesMDXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • MDXG is valuated correctly with a Price/Earnings ratio of 14.22.
  • MDXG's Price/Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 96.37% of the companies in the same industry.
  • MDXG's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.97.
  • The Price/Forward Earnings ratio is 45.63, which means the current valuation is very expensive for MDXG.
  • 90.63% of the companies in the same industry are more expensive than MDXG, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of MDXG to the average of the S&P500 Index (27.96), we can say MDXG is valued expensively.
Industry RankSector Rank
PE 14.22
Fwd PE 45.63
MDXG Price Earnings VS Forward Price EarningsMDXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaper than 97.71% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 97.90% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.35
EV/EBITDA 9.18
MDXG Per share dataMDXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • MDXG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MDXG has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as MDXG's earnings are expected to decrease with -5.49% in the coming years.
PEG (NY)0.89
PEG (5Y)N/A
EPS Next 2Y-37.8%
EPS Next 3Y-5.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MDXG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MIMEDX GROUP INC

NASDAQ:MDXG (2/13/2026, 8:23:46 PM)

After market: 5.12 0 (0%)

5.12

+0.03 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29
Earnings (Next)03-04
Inst Owners71.94%
Inst Owner Change-0.61%
Ins Owners1.79%
Ins Owner Change-0.11%
Market Cap758.27M
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target10.61 (107.23%)
Short Float %4.36%
Short Ratio7.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)-14.75%
PT rev (3m)-14.75%
EPS NQ rev (1m)-30.16%
EPS NQ rev (3m)-15.39%
EPS NY rev (1m)-21.43%
EPS NY rev (3m)1.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.73%
Valuation
Industry RankSector Rank
PE 14.22
Fwd PE 45.63
P/S 1.93
P/FCF 11.35
P/OCF 11.18
P/B 3.17
P/tB 3.64
EV/EBITDA 9.18
EPS(TTM)0.36
EY7.03%
EPS(NY)0.11
Fwd EY2.19%
FCF(TTM)0.45
FCFY8.81%
OCF(TTM)0.46
OCFY8.95%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.89
PEG (5Y)N/A
Graham Number3.62
Profitability
Industry RankSector Rank
ROA 12.8%
ROE 17.09%
ROCE 20.67%
ROIC 15.15%
ROICexc 33.2%
ROICexgc 44.66%
OM 13.73%
PM (TTM) 10.38%
GM 81.99%
FCFM 16.98%
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.27
Debt/EBITDA 0.25
Cap/Depr 6.96%
Cap/Sales 0.26%
Interest Coverage 36.69
Cash Conversion 98.8%
Profit Quality 163.64%
Current Ratio 4.41
Quick Ratio 3.95
Altman-Z 7.93
F-Score6
WACC12.23%
ROIC/WACC1.24
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y16.07%
EPS Next 2Y-37.8%
EPS Next 3Y-5.49%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year18%
Revenue Next 2Y7.11%
Revenue Next 3Y9.76%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year63.46%
EBIT Next 3Y18.36%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A

MIMEDX GROUP INC / MDXG FAQ

Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?

ChartMill assigns a fundamental rating of 5 / 10 to MDXG.


Can you provide the valuation status for MIMEDX GROUP INC?

ChartMill assigns a valuation rating of 6 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Fairly Valued.


What is the profitability of MDXG stock?

MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.


What is the financial health of MIMEDX GROUP INC (MDXG) stock?

The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.


What is the earnings growth outlook for MIMEDX GROUP INC?

The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to grow by 16.07% in the next year.